- Research
- Company trackers
- Stryker
Stryker tracker
What Stryker is building, from Mako surgical robots to new joints and clot removal devices, plus its sales by business quarter by quarter, results and the latest news.
Sales by business
Stryker has two businesses. MedSurg and Neurotechnology covers hospital equipment, surgical tools, endoscopy, clot removal and brain surgery. Orthopaedics covers joint replacements, trauma implants and the Mako robot.
Jul–Sep 2026
- MedSurg and Neurotechnology+9.2% on a year ago$3.66bn56%
- Orthopaedics+5.7% on a year ago$2.86bn44%
The last five quarters
| Q2 2025Apr–Jun 2025 | Q3 2025Jul–Sep 2025 | Q1 2026Jan–Mar 2026 | Q2 2026Apr–Jun 2026 | Q3 2026Jul–Sep 2026 | |
|---|---|---|---|---|---|
| MedSurg and Neurotechnology | $3.31bn | $3.36bn | $3.21bn | $3.63bn | $3.66bn |
| Orthopaedics | $2.72bn | $2.70bn | $2.81bn | $2.96bn | $2.86bn |
Stryker moved some businesses between the two in 2026 and restated past quarters. It has not filed the new split for Oct–Dec 2025, so that quarter is missing. Sources: Q2 2025, Q3 2025, Q1 2026, Q2 2026, Q3 2026
Q3 2026 results
Published 29 Oct 2026. Sales rose 7.7% to $6.52bn, which Stryker said was below its own hopes. Net earnings fell 12% to $753m because of one-off charges; adjusted earnings per share rose 10% to $3.52. It narrowed its 2026 forecast.
In brief
- Sales of $6.52bn, up 7.7%, driven by selling more units.
- MedSurg and Neurotechnology sales rose 9.2% to $3.66bn; Orthopaedics rose 5.7% to $2.86bn.
- Endoscopy grew 14% and Vascular 8%; knees grew 1% and hips fell 1%.
- Net earnings of $753m, down 12%, after one-off charges. Adjusted earnings per share rose 10% to $3.52.
- Bought back $1.0bn of its own shares and added $3.0bn to the buyback plan.
- Now expects 2026 underlying sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90.
- Kevin Lobo hands over as chief executive to Spencer Stiles on 1 Jan 2027 (announced 6 Oct).
Against a year ago (Q3 2025)
| Q3 2025 | Q3 2026 | Change | |
|---|---|---|---|
| Sales | $6.06bn | $6.52bn | up +7.6% |
| MedSurg and Neurotechnology | $3.36bn | $3.66bn | up +9.2% |
| Orthopaedics | $2.70bn | $2.86bn | up +5.7% |
| Net earnings | $859m | $753m | down −12% |
Red and green show whether a change is good or bad for Stryker, so more spending shows in red.
Sales
Net earnings
The business split for Q3 2025 is Stryker’s restated figure. Adjusted figures leave out one-off charges. Stryker Q3 2026 results, 29 Oct 2026
Products and progress
Where each Stryker product has got to, from first announcement to widely available. Checked against Stryker’s Q3 2026 results (29 Oct 2026) and its announcements.
Robots
-
Mako robotic surgery Widely available
Over 2.5 million Mako operations in 47 countries (Jul 2026)
A robotic arm that helps surgeons fit knee and hip replacements to a 3D plan of the patient. Mako 4 is the latest model. Stryker news, 16 Jul 2026
-
Mako RPS handheld robot Early rollout
Full US launch 16 Jul 2026, after a limited launch in Feb 2026
A handheld robotic saw for knee replacements that keeps each cut on the plan, with no cutting blocks needed. Stryker news, 16 Jul 2026
-
Mako Shoulder Early rollout
Full market release (Mar 2026); coming to Mako 4 in the second half of 2026
Mako for reverse shoulder replacements, with Tornier implants and Blueprint planning software. Stryker news, 3 Mar 2026
Joints
-
Triathlon Gold knee Early rollout
Launched Mar 2026
A 3D-printed knee part with a gold-coloured titanium nitride coating, for patients sensitive to some metals. Stryker news, 3 Mar 2026
-
Incompass ankle replacement Early rollout
Prophecy planning now available with it (16 Sep 2026)
A total ankle replacement. Prophecy plans each operation from the patient’s own scans. Stryker news, 16 Sep 2026
-
FiberLocker rotator cuff repair Early rollout
Stryker completed buying its maker, ZuriMED, 26 Oct 2026
Strengthens the stitching when a torn shoulder tendon is repaired. Stryker news, 26 Oct 2026
Instruments
-
New surgical power tools Early rollout
TPX HD and BPX cordless tools introduced Mar 2026
Drills and saws for joint revision, trauma, foot and ankle and hand surgery. Stryker news, 3 Mar 2026
Vascular
-
Clot removal (Inari) Widely available
Vascular sales of $566m in Jul–Sep 2026, up 8%
FlowTriever and ClotTriever pull large blood clots out of veins and lungs. Stryker bought Inari for $4.9bn in Feb 2025. Stryker Q3 2026 results
-
Pulse lithotripsy (Amplitude Vascular) Testing
Bought May 2026; US trials under way
A balloon that sends pressure waves to crack hard calcium inside narrowed arteries so they can be opened. MedTech Dive, 8 May 2026
Hospital
-
Endoscopy Widely available
$1.02bn of sales in Jul–Sep 2026, up 14%
Cameras, lights and tools for keyhole surgery, and kit for operating theatres. Stryker Q3 2026 results
-
Medical (beds, defibrillators) Widely available
$1.08bn of sales in Jul–Sep 2026, up 10%
Hospital beds, stretchers, emergency care equipment and LIFEPAK defibrillators. Stryker Q3 2026 results
-
Neuro Cranial Widely available
$670m of sales in Jul–Sep 2026, up 5%
Tools and implants for brain and skull surgery, now part of the Instruments business. Stryker Q3 2026 results
What’s new
- Filing Company announcement: results or delivery report SEC,
- News Stryker completes ZuriMED takeover MedTech Dive,
- Filing Company announcement: board or management change, statement to investors SEC,
The last 30 days. Headlines link to the full stories on the publishers’ own sites.
Numbers
Sales each quarter
Net profit each quarter
| Quarter | Months | Sales | Net profit |
|---|---|---|---|
| Q3 2026 | Jul–Sep 2026 | $6.52bn | $753m |
| Q2 2026 | Apr–Jun 2026 | $6.59bn | $1.28bn |
| Q1 2026 | Jan–Mar 2026 | $6.02bn | $745m |
| Q4 2025 | Oct–Dec 2025 | $7.17bn | $849m |
| Q3 2025 | Jul–Sep 2025 | $6.06bn | $859m |
| Q2 2025 | Apr–Jun 2025 | $6.02bn | $884m |
| Q1 2025 | Jan–Mar 2025 | $5.87bn | $654m |
From Stryker’s results filed with the SEC; newer quarters appear automatically, with the business split added after each report is checked.
Directors’ share deals
Directors and senior staff must tell the SEC within two business days when they buy, sell or are given shares.
| Reported | Who | What happened |
|---|---|---|
| 28 Sep 2026 | Preston Wendell WellsVP, Chief Financial Officer | Other 109 shares |
| 24 Sep 2026 | Preston Wendell WellsVP, Chief Financial Officer | Other 2,739 shares |
| 2 Sep 2026 | Mary K BrainerdDirector | Bought 131 shares at $204.09 ($26,736) |
| 26 Aug 2026 | Dylan Bram CrottyGroup President | Sold 441 shares at $328.61 ($144,915) |
| 20 Aug 2026 | Ronda E StrykerDirector | Sold 350,000 shares at $336.50 ($118m) |
| 18 Aug 2026 | Debra KingSee Remarks | Sold 826 shares at $336.30 ($277,787) |
| 4 Aug 2026 | Kimberly Ann MontagninoVP, Chief Comm. Officer | Shares kept back for tax 155 shares |
| 4 Aug 2026 | Debra KingSee Remarks | Shares kept back for tax 533 shares |
From Form 4 filings on SEC EDGAR. ‘Used options’ means turning share options into shares; it is not a purchase on the market.
Share price
Open the full chartChart by TradingView. Prices may be delayed. This page is not investment advice.
Timeline
- Jan 2027Spencer Stiles becomes chief executive.
- Jul 2026Fully launches the Mako RPS handheld robot in the US.
- Feb 2025Completes the $4.9bn purchase of Inari Medical.
- Dec 2013Buys MAKO Surgical, maker of the Mako robot.
- 1941Dr Homer Stryker starts the company in Kalamazoo, Michigan.
On X
Posts worth seeing will be added here. Meanwhile, these are the accounts to follow:
What do you think?
Share your view on Stryker with other ChartsView members.
Start a Stryker thread on the forumWhere this comes from
- US filings, results and insider deals: SEC EDGAR
- Sales by business: Stryker’s quarterly results
- Product news: Stryker newsroom
- Products, cities and timeline: checked by ChartsView against the company’s own reports, last on 29 Oct 2026.
All sources are free and public. Data is collected each morning and refreshed through the day. This page is for information only and is not investment advice.
ChartsView is independent and is not connected with, or endorsed by, Stryker Corporation. The company’s name is used only to say who this page is about.